Huadong Medicine Co., Ltd Sustainability Profile
Huadong Medicine Co., Ltd., a prominent player in the pharmaceutical industry, is headquartered in China (CN) and operates extensively across various regions. Founded in 1993, the company has established itself as a leader in the development, manufacturing, and distribution of high-quality pharmaceutical products. Specialising in innovative medicines, Huadong Medicine focuses on areas such as oncology, cardiovascular health, and central nervous system disorders. Their commitment to research and development has led to the creation of unique formulations that address unmet medical needs, setting them apart in a competitive market. With a strong market position, Huadong Medicine has achieved significant milestones, including numerous product approvals and partnerships that enhance its global reach. The company’s dedication to quality and innovation continues to drive its success in the ever-evolving healthcare landscape.
DitchCarbon Score
How does Huadong Medicine Co., Ltd's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Huadong Medicine Co., Ltd's score of 26 is lower than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Huadong Medicine Co., Ltd's reported carbon emissions
In 2023, Huadong Medicine Co., Ltd reported total emissions of approximately 152.1 million kg CO2e, with Scope 1 emissions accounting for about 14.3 million kg CO2e. The previous year, 2022, the company recorded total emissions of approximately 108.6 million kg CO2e, with Scope 1 emissions at about 11.3 million kg CO2e. This indicates a significant increase in emissions from 2022 to 2023. Currently, Huadong Medicine has not set any specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or commitments to the Science Based Targets initiative (SBTi). The company does not disclose Scope 2 or Scope 3 emissions data, which limits the understanding of its overall carbon footprint. As a pharmaceutical company headquartered in China, Huadong Medicine's emissions profile reflects the broader industry context, where many organisations are increasingly focusing on sustainability and carbon reduction strategies. However, without specific commitments or targets, the company's climate action remains unclear.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 11,305,600 | 00,000,000 |
| Scope 2 | - | - |
| Scope 3 | - | - |
How Carbon Intensive is Huadong Medicine Co., Ltd's Industry?
How Carbon Intensive is Huadong Medicine Co., Ltd's Location?
Huadong Medicine Co., Ltd's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Huadong Medicine Co., Ltd has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.